Mrs. Maria Kirsten Leslie Thomas, MFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 416 Allegheny St Ste 103, Hollidaysburg, PA 16648 Phone: 814-937-5129 |
Mrs. Lynn Michelle Johnson, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 511 Allegheny St Ste 1, Hollidaysburg, PA 16648 Phone: 814-931-6791 |
News Archive
Medtronic, Inc. today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI SureScan® pacing leads, which are approved for use during Magnetic Resonance Imaging (MRI). Medtronic introduced the first MR-Conditional pacemaker system in the world in 2008 and in the U.S. in 2011.
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a new integration contract with Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians. Alpha II's ClaimStaker software will soon be offered as an integrated solution to the Allscripts client base currently using MyWay, Tiger PM and Vision PM. Alpha II's CodeWizard will also be integrated into the Allscripts MyWay application. Estimated date of completion for the integrations is Q1 2011 for MyWay and Tiger, and Q2 2011 for integration into Vision.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.
The recent legalization of recreational marijuana (cannabis) use in California, Colorado, and Washington reflect the sweeping changes in the attitudes and perceptions towards marijuana use in the United States.
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
› Verified 1 days ago